AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Probable ATP-dependent RNA helicase DDX52

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9Y2R4

UPID:

DDX52_HUMAN

Alternative names:

ATP-dependent RNA helicase ROK1-like; DEAD box protein 52

Alternative UPACC:

Q9Y2R4; Q86YG1; Q8N213; Q9NVE0; Q9Y482

Background:

The Probable ATP-dependent RNA helicase DDX52, also known as ATP-dependent RNA helicase ROK1-like and DEAD box protein 52, plays a crucial role in ribosome biogenesis, akin to its counterparts. It is speculated to regulate cell cycle progression by modulating the translation of mRNAs with a terminal oligo pyrimidine (TOP) motif in their 5' UTRs, including GTPBP4.

Therapeutic significance:

Understanding the role of Probable ATP-dependent RNA helicase DDX52 could open doors to potential therapeutic strategies, especially in the realm of diseases where ribosome biogenesis and cell cycle regulation are compromised.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.